SOUTH SAN FRANCISCO, Calif., Oct. 1, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (KaloBios) (NASDAQ:KBIO) today announced the completion of its public offering of 8,625,000 shares of common stock at $4.00 per share, which included 1,125,000 shares issued upon the exercise in full of the underwriters' option to purchase additional shares. The net offering proceeds to KaloBios were approximately $32,085,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the company.
Leerink Swann LLC acted as sole book-running manager for the offering. William Blair & Company, L.L.C., Needham & Company LLC, and JMP Securities LLC acted as co-managers for the offering.
A registration statement relating to these securities was declared effective by the SEC on September 18, 2013. The offering was made only by means of a prospectus, copies of which may be obtained by contacting Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by calling (800) 808-7525.
This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat severe medical conditions with a primary clinical focus on respiratory diseases and cancer.
Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
Joan E. Kureczka
Tel: (415) 821-2413
Mobile: (415) 690-0210
SOURCE KaloBios Pharmaceuticals, Inc.